Hypertension Drugs: The regional make-up of investment is shifting
Lifestyle habits such as diet, exercising, and smoking, rising geriatric population, government awareness programs, increasing prevalence of hypertensive heart diseases, coronary artery diseases, stroke, aortic aneurysm, peripheral artery disease and chronic kidney disease are the major drivers of global hypertension drugs market.
According to Goldstein Research, Hypertension Drugs market size is set to reach USD 33.1 billion by 2024, at a CAGR of 1.12% over the forecast years owing to change in lifestyle responsible for high blood pressure.
Geographically, North America dominates the hypertension drug market with acquiring 40% market share due to increasing geriatric population and increasing awareness about the hypertension therapies.
Novartis to fix Hypertension Franchise by Combination Pills
Novartis will get back its leadership post in blood pressure therapies due to the generic intrusion on its flagship “Diovan”, anti-hypertensive drug. With no novel agents in the research pipeline, the drugmakers are reaching into the life-cycle playbook and launching new fixed-dose combinations to compensate the market share loss. Including Diovan, seven medicines in BP franchise are available worldwide for 81% of total pharmaceutical sales in three biggest markets (the United States 33%, Europe 38%, and Japan 10%).
Global Hypertension Drugs Market
The Report contains a detailed overview of the global hypertension drugs market in terms of market segmentation by analysis basis and therapy type.
Further, for the in-depth analysis, the report encompasses the industry growth drivers, market challenges, risk analysis, market attractiveness, BPS (Base Point Scale) analysis, Porter’s five force model and SWOT analysis.
Global Hypertension Drugs Market report also provides competitive outlook for some of the major players which includes profiling of companies such as Lupin Limited, Novartis AG, Sun Pharmaceuticals LLC, Daiichi - Sankyo, Pfizer Inc., Sanofi S.A, AstraZeneca Plc., Johnson & Johnson Ltd., Boehringer Ingelheim, and Merck & Co, Roche, Abbott, GlaxoSmithKline plc., AstraZeneca, Bayer AG, Gilead, Actelion, Symplmed Pharmaceuticals, Takeda Pharmaceuticals, United Therapeutics, Valeant Pharmaceuticals, XOMA, Yuhan, Ono Pharmaceutical, Northern Therapeutics, Mast Therapeutics, Eiger BioPharmaceuticals. The company profiles include business strategy, geographical revenue distribution, major information of the companies which encompasses business outlook, products, services and industries catered, financial analysis of the company and recent developments.
Overall, the report represents comprehensive synopsis on the global hypertension drugs market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market-centric strategies according to the ongoing and expected trends in the future.
Based in the US, Goldstein Research currently has a strong presence in the American and Asian countries. In the next five years, we strive to expand our reach to 50+ nations spanning across Europe, Asia and parts of the Middle East and Africa. We strive to realize a strong brand presence globally through our quality research and forecasting solutions.
Our mission is simple: to develop insightful business solutions, help our clients make powerful future decisions to keep them well ahead of the game which is the market, and leave a mark across businesses and communities through our well-defined ideas and clear-cut forecasts. Backed up by reliable research and impactful statistics, our business solutions empower our clients to grow at a fast pace despite unsettling fluctuations in the market. We believe in a vigorous examination of the current market scenario and build around creative ideas and approaches that are most suitable to our clients’ needs and business agenda.